The global vulvodynia treatment market was worth around $5.4 billion in 2021 and is predicted to grow to around $8 billion by 2028 at a CAGR rate of 7% over the forecast period.
The global vulvodynia treatment market was worth around $5.4 billion in 2021 and is predicted to grow to around $8 billion by 2028 at a CAGR rate of 7% over the forecast period. In this report, we will cover the full overview, growth drivers, opportunities, and obstacles of the global vulvodynia treatment market from 2022 to 2028
Vulvodynia is vulvar pain or some kind of discomfort with respect to reproductive stages. All the comorbid symptoms and the pain associated with the disease will complicate any kind of movement or management. It also triggers some biological, psychological, and interpersonal factors that aggravate the illness to some extent.
The pain and discomfort increase while the vulva expands and contracts. That kind of movement is called vulvodynia. This problem is not easily diagnosable. The emergence of this condition affects a woman’s life by disrupting her sex life and also her efforts to exercise. It is classified into two types, such as generalized vulvodynia and localized vulvodynia.
It is usually caused due to improper tampon insertion, prolonged sitting, or horseback riding. Sometimes sexual intercourse or extreme gynecological examinations along with wearing tight undergarments can also cause this illness.
This occurs to women of all ages. Even though the disease is not fatal, this comes across as a life-disrupting illness that needs immediate cure or treatment. The reproductive health of women is also affected to some extent.
Covid-19 Impact:
Covid-19 has a delirious impact on the global vulvodynia treatment market. All medical procedures and treatment took a hit because people were restricted from going to hospitals or clinics. They were cooped up at home and take self-treatments for any kind of minor illnesses. The demand for vulvodynia treatment went down massively due to people’s hesitation on taking any cure because of curfews and lockdowns. There was also a shortage of raw materials, equipment, and drugs for the treatment because of commutation issues during the pandemic. All of this led to a deprecation in the market rate.
Growing focus on women's healthcare issues propels the market growth
The major growth drivers of the global vulvodynia treatment market are the growing focus on women's healthcare and the awareness that has crept in recent times. There are multiple advancements in healthcare facilities to ease the treatment of vulvodynia to a great extent. This actually triggers huge demand for vulvodynia treatment, thus making more people to opt for it. The access to the raw materials and generic products for the treatment methods are quite flexible and abundant, thus improving the consumption of the treatment, thereby inducing market growth.
Technological advancement in the field of vulvodynia treatment methods also improves its popularity. Many companies have now started focusing on bringing some technological advancements in the vulvodynia drug, which propels growth in the market.
There is some growing awareness of the disease in recent times, which seems to have increased its consumption. The growing knowledge amongst gynecologists is also supporting the market to a large extent. The growing leverage of anesthetics, lidocaine gels, and creams to reduce the pain also drives market growth exclusively.
Female sexual dysfunction has become a prominent problem and also awareness about it has increased in recent times. Painkillers for that illness have actually triggered more focus on the treatment method, and medications have been prescribed in large quantities.
There is also a growing trend of economic and financial burden because of the disease, which boosts the demand for vulvodynia treatment. Multidisciplinary approaches in vulvodynia treatment also trigger market growth to a large extent.
Limited awareness of the disease and the side effects hamper market growth
The limited awareness of the disease and the lack of effective treatment methods for the diseases restrain the market growth of vulvodynia treatment. Apart from this, the treatment is also touted to bring some considerable side effects because of the heavy medications used. All these factors curtail the expansion of the vulvodynia treatment market.
Growing research on improving the treatment methods of vulvodynia offers the opportunity for market expansion
The development activities and research going on in devising a suitable treatment method for vulvodynia trigger opportunities for market growth. Along with this, the therapeutic intervention and modification of drugs used in the process also greatly render global vulvodynia treatment market expansion opportunities.
The lack of awareness of such a disease poses a challenge to the global market.
Many developing countries suffer from a lack of awareness and knowledge about this illness. The treatment methods and the lack of infrastructures & medical equipment needed for its cure are also in shortage in many regions. This factor acts as a challenge for the global market expansion and mass leverage.
Side effects of the treatment also challenge the market growth
The treatment involves therapeutic intervention which appears to bring lots of side effects that affect people in different ways. This causes people to refuse treatment or a cure for this disease, which in turn poses a challenge to market growth.
The global vulvodynia treatment market is fragmented into types, indications, end-users, and regions. The type is classified into biofeedback therapy, intralesional injections, and oral treatment. The indication is divided into generalized vulvodynia and localized vulvodynia. The end users are hospital pharmacies, retail pharmacies, and online pharmacies.
Recent Development:
The global market is likely to be dominated by North America during the forecast period
North America dominates the global vulvodynia treatment market due to the prevalence of these diseases and infertility issues. The research and ongoing development activities in this region also support market growth. Western Europe trails as the next best contributor of the market share, owing to the growing popularity of vulvodynia treatment procedures. The growing medical research also improves the consumption of this treatment. There is a rapid progression of generic medications in the Asia Pacific region, which makes it the third-most lucrative market contributor.
Report Scope:
By Type
By Indication
By End-Users
By Region
FrequentlyAsked Questions
The major growth drivers of the vulvodynia treatment market are the growing focus on women's healthcare and the awareness that has crept in recent times. There are multiple advancements in healthcare facilities to ease the treatment of vulvodynia to a great extent.
The Global Vulvodynia treatment market was worth around $5.4 billion in 2021 and is predicted to grow to around $8 billion by 2028 at a CAGR rate of 7% over the forecast period.
North America dominates the global vulvodynia treatment market due to the prevalence of these diseases and infertility issues. The research and ongoing development activities in this region also support market growth.
Major players in the vulvodynia treatment market are Allergan plc, Johnson & Johnson Services Inc, Pfizer Inc, GlaxoSmithKline plc, AstraZeneca plc., Eli Lilly, Sanofi, Hisamitsu Pharmaceutical Co. Inc, and National Vulvodynia Association.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed